Su, Y., Li, X., Ma, J., Zhao, J., Liu, S., Wang, G., . . . Ge, Y. (2017). Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol.
Παραπομπή Chicago StyleSu, Yongwei, et al. "Targeting PI3K, MTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity against AML Ex Vivo." Biochem Pharmacol 2017.
Παραπομπή MLASu, Yongwei, et al. "Targeting PI3K, MTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity against AML Ex Vivo." Biochem Pharmacol 2017.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.